Sun Pharma Signals Slower Growth Trajectory for FY27 Amid Evolving Regulatory Landscape
Sun Pharmaceutical Industries Ltd, India’s largest drugmaker, announced this week that it expects revenue growth to decelerate to the high single-digit range for the 2027 fiscal year. This projection follows a robust 11.9% revenue increase recorded in fiscal year 2026, marking a strategic pivot as the company navigates tightening global regulatory standards and complex macroeconomic…